Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1245020.RAfsYN0Q18Aj2Bhwx8JYeiY7Edt6iftADtAjSy79gUaAM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1245020.RAfsYN0Q18Aj2Bhwx8JYeiY7Edt6iftADtAjSy79gUaAM130_assertion type Assertion NP1245020.RAfsYN0Q18Aj2Bhwx8JYeiY7Edt6iftADtAjSy79gUaAM130_head.
- NP1245020.RAfsYN0Q18Aj2Bhwx8JYeiY7Edt6iftADtAjSy79gUaAM130_assertion description "[The targeted therapies dabrafenib and neratinib are being tested separately in subsets of patients with BRAF- and HER2-mutant non-small cell lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1245020.RAfsYN0Q18Aj2Bhwx8JYeiY7Edt6iftADtAjSy79gUaAM130_provenance.
- NP1245020.RAfsYN0Q18Aj2Bhwx8JYeiY7Edt6iftADtAjSy79gUaAM130_assertion evidence source_evidence_literature NP1245020.RAfsYN0Q18Aj2Bhwx8JYeiY7Edt6iftADtAjSy79gUaAM130_provenance.
- NP1245020.RAfsYN0Q18Aj2Bhwx8JYeiY7Edt6iftADtAjSy79gUaAM130_assertion SIO_000772 25477108 NP1245020.RAfsYN0Q18Aj2Bhwx8JYeiY7Edt6iftADtAjSy79gUaAM130_provenance.
- NP1245020.RAfsYN0Q18Aj2Bhwx8JYeiY7Edt6iftADtAjSy79gUaAM130_assertion wasDerivedFrom befree-2016 NP1245020.RAfsYN0Q18Aj2Bhwx8JYeiY7Edt6iftADtAjSy79gUaAM130_provenance.
- NP1245020.RAfsYN0Q18Aj2Bhwx8JYeiY7Edt6iftADtAjSy79gUaAM130_assertion wasGeneratedBy ECO_0000203 NP1245020.RAfsYN0Q18Aj2Bhwx8JYeiY7Edt6iftADtAjSy79gUaAM130_provenance.